On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Khiron Life Sciences Corp. (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) Poised to Be a Global Medical Cannabis Frontrunner

Khiron Life Sciences (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) (“Khiron” or the “Company”) is a vertically integrated cannabis leader with core operations in Latin America and Europe. The company trusts in the vast benefits of medical cannabis and is committed to improving the life quality of patients and consumers through the applied use of cannabis and technology.

Khiron is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products, having achieved first sales in March 2020 and medical cannabis insurance coverage in December 2020. Additionally, the Company has commenced medical cannabis sales in the United Kingdom, Peru, and Germany, with Mexico and Brazil also anticipated this year. Khiron operates six wholly owned health centres in Colombia, where it completed more than 100,000 patient transactions in 2020. The Company is currently expanding patient access in Latin America through satellite clinics, with plans to accelerate growth in Europe by leveraging assets developed in Colombia, including clinical IP, genetics, and data.

Khiron has successfully exported its registered cannabis strains, in the form of live clones, from Colombia to Europe. This significant milestone represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets.

Tejinder Virk (Khiron’s European Managing Director and President) explains the process of certifying the company’s cannabis strains for export to Europe by way of clones:

“A clone is a cannabis plant that is a genetic copy of a mother plant. These clones were cut from our THC and CBD bearing mother plants in Colombia, which are used to make medicines for thousands of our patients in Latin America (over 10,000 prescriptions to date and growing quickly!). Europe has a population of nearly 748 million people and there is enormous patient need for cannabis-based medicines. However, doctors in Europe need solid clinical evidence to confidently prescribe medical cannabis for ailments such as pain, sleep or anxiety. By replicating our Colombian magistrals as EU GMP certified medicines, we aim to provide European doctors with practical clinical evidence from Colombia. This will also help ensure European patients get safe and efficacious treatment. The achievement demonstrates our global regulatory leadership and ability to export our intellectual property to other markets.”

As the management team executes its growth strategy throughout the United Kingdom and Germany by introducing branded extracts and dried flower products, Khiron continues to validate its patient-centric strategy with over 13,000 prescriptions written to date amid plans to reach 1 million patients and consumers by 2024.

Most recently, the first shipment of Khiron-branded EU-GMP certified cannabinoid-based medicine was successfully completed, providing immediate access to the German market through Khiron’s distribution partner, Nimbus Health GmbH, a leading EU-GMP/GDP certified medical cannabis distributor in Germany, with a network of over 300 pharmacies. Khiron teams continue to educate physicians with plans to leverage clinical evidence from both the UK and Colombia. This major milestone represents a new revenue stream for Khiron and positions Khiron’s European team to execute on its German medical strategy.

As a revolutionary, patient-focused, global leader of medical cannabis from Latin America, Khiron offers products that are manufactured in GMP-GEP compliant facilities in Colombia and are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42). Khiron believes, with its extremely skilled management team, that the company will be a frontrunner in the global medical cannabis market, which is expected to reach $44 billion by 2024 (https://nnw.fm/UOtq3) and $84 billion by 2028 (https://nnw.fm/pNkrb)

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217